LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

Contributed by: Business Wire

Logo

Tags

Research

Pharmaceutical

Biometrics

Mental Health

Medical Devices

Hospitals

Clinical Trials

Science

Surgery

Cardiology

FDA

Health

LivaNova PLC

More Like This

LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services